经导管肝动脉栓塞治疗肝癌的远期疗效观察  

Long-term Result of Transcatheter Hepatic Artery Embolization for Primary Hepatic Carcinoma

作　　者：陈晓明[1] 罗鹏飞[1] 邵培坚[1] 周泽健[1] 马壮[1] 符力[1] 李伟科[1] 李勇[1] 

机构地区：[1]广东省人民医院肿瘤科,广州市510080

出　　处：《中国肿瘤临床》1997年第11期841-844,共4页Chinese Journal of Clinical Oncology

摘　　要：262例原发性肝癌行经导管肝动脉注射碘油抗癌药混悬剂栓塞化疗（LP－TAE）后随访4～5年，生存3年以上52例，其中27例生存4年以上，8例生存5年以上，3、4、5年累计生存率分别为21．04％，11．64％和4．03％（寿命表法）。与同期生存3年以内的210例对照比较，结果表明病程分期、肝功能、肿瘤大小与生长方式、肿瘤供血丰富程度、是否伴有门脉癌柱与A－V分流、是否加用明胶海绵栓塞、Lp－TAE后碘油沉积范围、治疗后肿瘤缩小程度、AFP是否降为正常、是否伴发肝内外转移是影响肝癌Lp－TAE远期疗效的重要因素。Two hundred and sixty-two patients with primary hepatic carcinoma treated with Lipiodol transcatheter hepatic artery embolization (Lp-TAE) were followed up for 4-5 years. Fifty-two of the patients survived for more than 3 years. Among them, 27 patients survived for more than 4 years and 8 patlents more than 5 years. The 3-, 4-, 5-year survival rates were 21. 04%, 11. 64% and 4. 03 % respectively. As compared with 210 cases who survived less than 3 years, it is demonstrated that clinical stage, impairment of liver function, tumor size, growing pattern, blood supply of tumor, presence of portal tumor thrombi and A-V shunt,use of gel form embolization,extent of Lipiodol deposition, shrinkage of the tumor,decline of AFP and presence of metastasis were the most important factors affecting the long-term effect of Lp-TAE in the treatment of primary hepatic carcinoma.

关 键 词：肝动脉栓塞 预后 肝肿瘤 药物疗法 

分 类 号：R735.7[医药卫生—肿瘤] R730.53[医药卫生—临床医学]